{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260420812445/en/Emerging-Data-for-Lantern-Pharma%E2%80%99s-Investigational-Drug-LP-300-Demonstrates-8.3-Month-Median-Progression-Free-Survival-in-Patients-with-EGFR-L858R-Lung-Cancer-After-Targeted-Therapy-Failure-%E2%80%94-With-No-Added-Toxicity", "message": "News view counter 671195 successfully enlarged"}